GTX Inc (NASDAQ:GTXI) issued financial report for the third quarter of 2017 and showcased upcoming milestones and recent accomplishments. Robert J. Wills, Ph.D., the Executive Chairman, expressed that during the quarter, they recorded a major milestone for the firm when they posted positive data from their first clinical study in stress urinary incontinence.
Notably, 18 out of 18 subjects who received enobosarm for 12-weeks responded. Also, these responses seem to be durable, lasting months’ post dosing. These thrilling results offered the basis for their recently started, placebo-controlled clinical study of enobosarm for the cure of SUI. Kenneth M. Peters, M.D., the principal investigator in the study, expressed that recent data indicates 50% of women report stress urinary incontinence, for which there exist no FDA-permitted pharmaceutical treatments.
An orally-available treatment would provide numerous benefits over current treatments including surgery. They would offer a significant new alternative that several women would select in order to resolve this medical problem.
Enobosarm, a SARM, is being assessed in Phase II clinical advancement for stress urinary incontinence, GTX’s lead indication. The company posted positive data from the Phase II proof-of-concept clinical study of enobosarm 3 mg given orally in post-menopausal women with Stress Urinary Incontinence. With the addition of the final subject completing treatment in the clinical study, results from the 18 evaluable subjects completing the needed 12-weeks of daily treatment demonstrated a clinically meaningful decline in stress leaks a day, versus baseline. The mean drop in stress leaks a day was 81% overall.
GTX reported that subjects are being followed for another 28-weeks post-treatment to evaluate the durability of treatment effect. Response durability for subjects who completed the 28-week observation stage has led in a 41% to 100% decline in stress leaks per day from baseline. For those subjects who have not completed this phase, the response durability, measured starting four weeks after dosing, was sustained.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.